Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET

Trial Profile

Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Bicalutamide; Flutamide; Nilutamide
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ANZUP ENZAMET; ENZAMET
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top